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ABSTRACT
Despite their physiological importance, selective
interactions between nuclear receptors (NRs) and
their cofactors are poorly understood. Here, we
describe a novel signature motif (F/YSXXLXXL/Y)
in the developmental regulator BCL11A that facili-
tates its selective interaction with members of the
NR2E/F subfamily. Two copies of this motif (named
here as RID1 and RID2) permit BCL11A to bind
COUP-TFs (NR2F1;NR2F2;NR2F6) and Tailless/TLX
(NR2E1), whereas RID1, but not RID2, binds PNR
(NR2E3). We confirmed the existence of endogen-
ous BCL11A/TLX complexes in mouse cortex
tissue. No interactions of RID1 and RID2 with 20
other ligand-binding domains from different NR
subtypes were observed. We show that RID1 and
RID2 are required for BCL11A-mediated repression
of endogenous c-globin gene and the regulatory
non-coding transcript Bgl3, and we identify COUP-
TFII binding sites within the Bgl3 locus. In addition
to their importance for BCL11A function, we show
that F/YSXXLXXL/Y motifs are conserved in other
NR cofactors. A single FSXXLXXL motif in the NR-
binding SET domain protein NSD1 facilitates its
interactions with the NR2E/F subfamily. However,
the NSD1 motif incorporates features of both
LXXLL and FSXXLXXL motifs, giving it a distinct
NR-binding pattern in contrast to other cofactors.
In summary, our results provide new insights into
the selectivity of NR/cofactor complex formation.
INTRODUCTION
Nuclear receptors (NRs) are structurally dynamic proteins
that selectively recruit coactivators and corepressors to
regulate gene expression. Docking of selected cofactors
with the NR ligand-binding domains (LBDs) is mediated
by LXXLL (1,2) and CoRNR box signature motifs (3–5).
Reports in the literature have identiﬁed potentially several
hundred cofactors that bind one or more of the 48 known
human NRs (www.NURSA.org). While some cofactors
can exhibit relatively promiscuous [e.g. p160s, RIP140
(1,2)] or highly selective [e.g. Moses (6)] NR binding pref-
erences, surprisingly little is known regarding how such
molecular selectivity is achieved.
We have investigated the molecular basis of interactions
between the orphan receptor COUP-TFII and the Kru¨ppel
zinc ﬁnger protein BCL11A (also known as CTIP1 and
Evi9) (7). BCL11A is a developmental regulator expressed
in haematopoietic and neural tissues whose overexpression
is associated with acute leukaemia and B-cell lymphoma
(8,9). Inactivating mutations in the BCL11A gene are
associated with sickle cell disease and b-thalassemias
(10–12), and it was subsequently shown that BCL11A is
a master regulator of fetal haemoglobin switching (13,14).
This is due to its function as a corepressor through associ-
ation with transcription factors such as COUP-TFII/
NR2F2 (7), GATA1 and SOX6 (13), although the molecu-
lar basis of these interactions is not well understood.
Moreover, BCL11A and its homologue BCL11B/CTIP2
may act in conjunction with other regulators such as
BCL6 (9), HP1a (15), SIRT1 (16), SUV39H1 (17), FOG1
(13) or the NuRD complex (18,19).
The COUP-TF/NR2F subfamily of NRs has a wide
range of functions in development, reproduction and
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homeostasis (20). Based on sequence homologies, they are
closely related to the RXR/NR2B and HNF4/NR2A
proteins, as well as the NR2E proteins TLX/NR2E1 and
PNR/NR2E3 (20,21). COUP-TFII is widely expressed in
mesenchymal tissues of the developing embryo and is
essential for angiogenesis and organogenesis including
retinal and neural development (22). BCL11A also
shows high expression in the developing and adult brain
(7,23,24). Previous work from Leid and colleagues
revealed that BCL11A and its homologue BCL11B are
both capable of direct binding to COUP-TFII and that
these proteins are present in high-molecular-weight
corepressor complexes in neuroblastoma cells and other
cell types (18,25). To understand the molecular basis of
BCL11A/COUP-TFII functional interactions in more
detail, we therefore set out to characterize the sequences
that facilitate the formation of this complex using protein–
protein interaction mapping studies.
MATERIALS AND METHODS
Plasmid constructs
Mammalian cell expression plasmids pcDNA3.1 FLAG-
BCL11A-XL, pcDNA3.1 HA-TLX and pcDNA3.1
HA-PNR-(89–410) were constructed by cloning modiﬁed
PCR fragments into the pcDNA3.1 vector. The FLAG-
BCL11A-XL L319A/Y656A/W659A, L318A and Y656A/
W659A and GFP-BCL11A-XL L319A/Y656A/W659A
constructs were generated by site-directed mutagenesis.
Plasmids pCH110-lacZ (26), pRARb2-Luc (27) and
pTL1-COUP-TFII (28) were gifts from E. Kalkhoven,
G.Folkers and M. Leid, respectively. Full-length cDNA
for BCL11A-XL and a GFP-BCL11A-XL construct were
provided by M.J.S. Dyer (U. Leicester).
For yeast two-hybrid expression, PCR fragments
encoding the required sequences were subcloned in-
frame into plasmids pBTM116mod and pASV3mod to
generate LexA DNA binding domain (DBD) and VP16
acidic activation domain (AAD) fusion constructs,
respectively. Construction of the LexA-SRC1-NID-(431–
761) expression vector has been described previously
(29). LexA–BCL11A-[(212–290), (212–295), (212–313),
(212–329), (212–376), (283–290), (295–376), (313–376),
(326–376), (283–329), (302–325), (306–225), (310–325),
(594–707), (594–687), (594–670), (611–641), (651–707),
(651–687) and (651–670)], LexA-NSD1-(790–818) and
LexA-COUP-TFII-LBD-(144–414) were generated by
PCR subcloning, or by ligation of phosphorylated
annealed oligonucleotide pairs into the pBTM116mod
vector. Site-directed mutagenesis was used to introduce
substitution mutations into constructs LexA-BCL11A-
(302–325), LexA-BCL11A-(310–325), LexA-BCL11A-
(651–670) and LexA-NSD1-(790–818). These include
mutations in RID1 (F315A; S316A; R317A; L319A;
R320A; L322A), RID2 (V655A; Y656A; S657A;
Q658A; W659A; L660A; G662A; Y663A) and NSD1
NR interaction domain (Y801A; K802A; F803A; S804A;
L806A; L807A; M808A; M809A; L810A; K811A;
D812A). The following AAD-fusion constructs were
generated by subcloning PCR fragments into the
pASVmod vector: VDR-LBD-(123–426), DAX-1-(1–140),
SHP-(106–461), Rev-erbb-LBD-(187–408), RORa-LBD-
(106–469), RORb-LBD-(98–459), HNF4g-LBD-(88–408),
TR2-LBD-(195–467), TR4-LBD-(218–530), TLX-LBD-
(100–385), PNR-LBD-(131–410), COUP-TFI-LBD-(151–
467), COUP-TFII-LBD-(144–414), EAR2-LBD-(121–399),
ERRa-LBD-(169–423), Nur77-(1–599), NURR1-(1–598),
LRH-1-LBD-(133–495) and GCNF-LBD-(138–475).
AAD-COUP-TFII-LBD C-terminal deletions 12-
(144–392), 11-(144–380) and 10-(144–359) or substitu-
tion mutations (F221A; V224A; R228A; I238A; V242A;
R246A) were generated by PCR and site-directed muta-
genesis. For PCR templates, NR cDNA vectors were
purchased from Open Biosystems. Constructs AAD-
[ERa-LBD-(282–595), AR-LBD-(626–919), RARa-LBD-
(200–462), RXRa-LBD-(200–462), TRb-LBD-(169–456)
and PPARg-LBD-(173–475)] were described previously
(29). NSD1 template cDNA was a gift from F. Cammas
and R. Losson.
GST-COUP-TFI-(151–467), GST-COUP-TFII-(144–414),
GST-PNR-(89–410) and GST-TLX-(100–385) were con-
structed by PCR subcloning into pGEX-DMH, a
modiﬁed version of pGEX-2TK vector (30). The construct
pGEX-2TK-GST-PPARg-LBD-(173–475) (31) was a gift
from E. Kalkhoven.
All constructs generated by PCR were sequenced to
conﬁrm their validity. The expression of fusion proteins
in yeast was monitored by western blotting (See
Supplementary Figures S1 and S2) using antibodies
recognizing VP16 AAD (Santa Cruz SC7545) or LexA
DBD (Millipore 06-719) as described previously (1).
Yeast two-hybrid interaction assays
Saccharomyces cerevisiae L40 (trp1, leu2, his3, ade2,
LYS2::(lexAop)4-HIS3, URA3::(LexAop)8-LacZ) was
co-transformed with LexA-fusion and AAD-NR-fusion
expression vectors using the lithium acetate method as
described (1). Single transformants containing the
desired plasmids were selected on appropriate media and
grown to late log phase in 15ml of selective medium (yeast
nitrogen base containing 2% w/v glucose and appropriate
supplements) in the presence of 106M cognate ligand or
vehicle. Preparation of cell-free extracts was by the glass
bead method, and b-galactosidase assays were performed
as described (1). Reporter b-galactosidase activities in the
presence or absence of ligand were determined for three
individual transformants for each condition, in replicated
experiments as stated. Ligands for RARa (all-trans
retinoic acid), RXRa (9-cis retinoic acid), ERa (17-b-
estradiol), AR (mibolerone), PPARg (roziglitazone),
TRb (Triiodothyronine) and VDR (cholecalciferol) were
purchased from Sigma.
GST pull-down assays
GST fusion proteins were expressed in Escherichia coli
BL21 using isopropyl-b-D-thiogalactopyranoside induc-
tion, and puriﬁed on glutathione-Sepharose beads
(Amersham Biosciences). The pcDNA3.1 BCL11A-XL
and associated mutant expression vectors were in vitro
transcribed/translated in the presence of [35S]-methionine
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in reticulocyte lysate (Promega) according to the manufac-
turer’s instructions. Equalised amounts of GST proteins
were incubated with 35S-radiolabelled protein in NETN
buffer (20mM Tris, pH 8.0, 100mM NaCl, 1mM EDTA,
0.5% NP-40) containing 1 complete protease inhibitors
(RocheMolecular Biochemicals) in the presence or absence
of 106M cognate ligand as described previously (32).
Samples were washed three times, and bound proteins
were separated by SDS-PAGE. Radiolabelled proteins in
dried gels were visualized by autoradiography.
Cell culture, transient transfections, reporter assays
U2OS and HEK293 cells were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS) and main-
tained as described previously (30). Twenty-four hours
prior to transfection, cells were replated in phenol red-
free DMEM supplemented with 5% dextran charcoal-
stripped FBS. Transient transfections were performed
using calcium phosphate co-precipitation. For reporter
assays, transfected DNA included pCH110-lacZ internal
control plasmid (500 ng/well), pRARb2-Luc (100 ng)
luciferase reporter plasmid and varying amounts of
pTL1-COUP-TFII, pcDNA3.1 HA-TLX, pcDNA3.1-
FLAG-BCL11A-XL or FLAG-BCL11A-XL L319A/
Y656A/W659A as indicated. Empty pcDNA3.1 expres-
sion vector was used to standardize the amount of trans-
fected DNA. After 16 h, fresh medium containing either
106M all trans-retinoic acid ligand (ATRA) or vehicle
was added. After a further 24 h, cells were harvested and
cell-free extracts were prepared and assayed for luciferase
activity using the Dual light Luciferase Assay System
(Applied Biosystems) and normalised to b-galactosidase
activities. Reporter assays were performed in triplicate.
Immunoprecipitation and western blots
For co-immunoprecipitation of recombinant proteins,
HEK293 cells were co-transfected with pTL1-COUP-
TFII, pcDNA3.1 HA-TLX or pcDNA3.1 HA-PNR-(89–
410) in combination with pcDNA3.1 FLAG-BCL11A-XL
ormutants. At 48 h post-transfection, the cells were washed
in PBS, harvested and nuclear extracts prepared (2mg) in
500 ml with Triton X-100 lysis buffer (50mM Tris-HCl
pH8, 150mM NaCl, 1% Triton X-100, 1mM PMSF,
1mM DTT and 1 protease inhibitor cocktail). Lysates
were equalised for protein content, pre-cleared by incuba-
tion with protein-G Plus Agarose (Santa-Cruz) and
FLAG-tagged proteins were immunoprecipitated using
1 mg of anti-FLAGM2 (A2220, Sigma) and 20 ml Protein-
G agarose overnight with gentle agitation. Agarose beads
were then washed ﬁve times in ice cold PBS and preci-
pitated proteins resolved by SDS-PAGE and detected by
Western blotting using anti-BCL11A (14B5, Santa Cruz),
anti-COUP-TFII (H7147, Abcam), anti-TLX (S-23, Santa
Cruz or anti-HA (F-7, Santa Cruz) as appropriate.
To assess co-immunoprecipitation of endogenous
proteins, dissected brain regions from wild-type mice
were snap frozen on dry ice and homogenized in Triton
X-100 lysis buffer (50mM Tris-HCl pH 8, 150mM NaCl,
1% Triton X-100, 1mM PMSF, 1mM DTT, 1 protease
inhibitors), sonicated and cleared by centrifugation.
Equalised amounts of protein were immunoprecipitated
with the appropriate antibody as described above. The
precipitates were resolved by SDS-PAGE for Western
blot analysis.
Immunohistochemistry
A 3-month-old male C57BL/6 J mouse was anaesthetized
and sacriﬁced by transcardial perfusion with 4%
paraformaldehyde in PBS. The brain was removed and
immersion ﬁxed in the ﬁxative for 24 h at 4C. Coronal
tissue sections were prepared after embedding in parafﬁn.
Immunohistochemical staining was performed using a
Dako Envision kit following manufacturer’s instructions,
and incorporating a microwave antigen retrieval step [10
min in 10mM sodium citrate (pH 6.0)]. Primary antibody
a-BCL11A (14B5, Santa Cruz) was used at a dilution of
1:50 and detected using DAB (brown) staining. Sections
were counterstained with haematoxylin (blue). Tissue
extractions were performed in accordance with local and
national rules under the Animals (Scientiﬁc Procedures)
Act UK 1986.
Electrophoretic mobility shift assay
Forward and reverse strands of nucleic acid probes were
subjected to 50-hydroxyl end labelling with [g32P]-ATP
using T4 polynucleotide kinase. The labelled probes were
annealed and puriﬁed on G-25 sephadex columns, before
being adjusted to 100 000 cpm/ml for use in binding assays.
Sequences of the probes used in this study are listed in
Supplementary Figure S3A. Nuclear extracts (NE) were
prepared from HEK293 cells transfected with
pTL1-COUP-TFII, pcDNA3.1 HA-TLX, pcDNA3.1
FLAG-BCL11A-XL or pcDNA3.1 (Mock). Expression
of the recombinant proteins were veriﬁed by western
blots (Supplementary Figure S4B). Indicated amounts of
NE were incubated with 1 ml nucleic acid probe, 1 mg
poly(dI:dC)·(dI:dC) and 3 mg bovine serum albumin in
electrophoretic mobility shift assay (EMSA) buffer
(20mM HEPES-KOH pH 7.9, 12% v/v glycerol, 50mM
KCl and 1mM DTT) to a ﬁnal volume of 10 ml. Binding
mixes were incubated at room temperature for 20min to
allow DNA/protein complex formation. Where appropri-
ate, speciﬁc antibodies for FLAG (A2220, Sigma) or
COUP-TFII (H7147, Abcam) were added to binding
mixes to validate the identity of protein/DNA complexes.
Binding mixes were loaded onto 5% polyacrylamide gels
and electrophoresed in 0.5 TBE prior to being visualized
by autoradiography.
Chromatin immunoprecipitation
Chromatin was prepared from DOHH2 or K562 cells
grown in RPMI supplemented with foetal bovine serum.
Approximately 1.5 107 cells per condition were ﬁxed
with 1% formaldehyde for 8min at room temperature
and subsequently quenched with 0.125 M glycine. Cells
were washed (3) in ice-cold PBS, resuspended in cell
lysis buffer (5mM Tris-Cl (pH 8.0), 85mM KCl, 0.5%
NP-40) and incubated for 10min on ice. Samples were
then harvested at 1000 rpm for 10min at 4C and the
supernatant aspirated. Chromatin was extracted from
Nucleic Acids Research, 2013, Vol. 41, No. 21 9665
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the nuclear pellet by resuspension in nuclei lysis buffer
(50mM Tris-Cl (pH 8.0), 10mM EDTA, 1% SDS) sup-
plemented with EDTA-free protease inhibitors (Roche)
for 10min on ice. Chromatin was sonicated using a
Diagenode water bath sonicator under conditions
optimized to give a DNA fragment length of 200–
500 bp. DNA content was measured using a bioanalyser
(Agilent) and fragment size veriﬁed by gel analysis.
Immunoprecipitation was performed with
PureProteome magnetic beads (Millipore) as per manufac-
turer’s protocol. In all, 10–25 mg of chromatin was used
for each IP which was incubated with 10 mg of speciﬁc
antibody for COUP-TFII (Active motif, 61213) or
BCL11A (Abcam, 19489) overnight at 4C. The beads
were washed (3) for 10min in 1 PBS-Tween and the
immunoprecipitate was eluted in 60 ml elution buffer
(0.2M glycine pH 2.5). Samples were then neutralized
with 1M Tris (pH 8.5), reverse-crosslinked by incubating
at 65C overnight and treated with protease K. DNA was
puriﬁed through Macherey-Nagel PCR puriﬁcation kit
according to manufacturer’s protocol. One microlitre of
ChIP-enriched DNA was used in a 20 ml quantitative real-
time polymerase chain reaction (qPCR) reaction as
described previously (33). qPCR reactions were done in
triplicate, and the samples were analysed on a 2%
agarose gel to verify that PCR products were of the
expected size. Primers were designed to amplify regions
selected by bioinformatic analysis, to detect recruitment
of factors at the human b-globin locus. Primer sequences
are listed in Supplementary Figure S3B.
RT-qPCR
K562 cells were maintained in RPMI supplemented with
10% FBS and 2mM glutamine at 37C in 5% CO2.
Approximately 2.5 105 cells were transfected with 1 mg
of GFP, GFP-BCL11AXL or GFP-BCL11AXL (L319A/
Y656A/W659A) using the Neon electroporation transfec-
tion system (Invitrogen) with the following parameters,
1350 v 10ms, 4 pulses. At 48 h post transfection, Bgl3
and g-globin gene transcripts were measured by RT-
qPCR, which was carried out as described previously
(33) using primers as described in Supplementary
Figure S3C. GAPDH transcript levels were used as the
reference gene, and assays were performed in triplicate.
RESULTS
F/YSXXLXXL/Y motifs mediate interaction of BCL11A
with COUP-TFII LBD
BCL11A has been previously reported to contain two
distinct regions (264–378 and 602–776) that can bind
COUP-TFII proteins (7). To identify the interacting se-
quences more precisely, yeast two-hybrid (Y2H) mapping
experiments were performed. Expression data for all two-
hybrid constructs and conﬁrmation of the lack of intrinsic
reporter activation activities are provided in
Supplementary Figures S1 and S2. Consistent with the
previous report, the BCL11A sequences 212–376 and
594–707 were both capable of binding to the COUP-
TFII LBD (144–414) independently of any added ligand
(Figure 1A). Extensive deletion mapping precisely
identiﬁed two short sequences (310–325 and 651–670;
termed here RID1 and RID2) that were sufﬁcient to
bind the COUP-TFII LBD (Figure 1A).
To identify residues within RID1 and RID2 that are
required for COUP-TFII LBD binding, alanine scan mu-
tagenesis was performed. As show in Figure 1B, the sub-
stitutions F315A, S316A, L319A or L322A abrogated the
binding of RID1 to COUP-TFII LBD. In contrast R317A
and R320A retained substantial COUP-TFII binding,
albeit that the reporter activity was 5-fold lower,
indicating these residues are less critical for complex for-
mation. Thus, the core sequence FSXXLXXL appears to
be essential for binding of the RID1 sequence to COUP-
TFII LBD. Similarly, V655A, Y656A, S657A, W659A,
L660A and Y663A substitutions in RID2 prevented its
interaction with COUP-TFII LBD whereas Q658A and
G662A had no deleterious effect on binding in yeast
two-hybrid assays (Figure 1B). This indicates that the
sequence motif VYSXWLXXY is required for the inter-
action of RID2 with COUP-TFII. Both RID1 and RID2
are well conserved in BCL11A homologues across species
(Figure 1C), and also within the closely related BCL11B
gene (Figure 4A), and are predicted by the PSIPRED
(http://bioinf.cs.ucl.ac.uk) algorithm to form amphipathic
a-helices similar to the LXXLL (1) and CoRNR box
motifs (3). Thus, we conclude that a core a-helical
sequence motif ﬁtting the consensus [F/Y]SXXLXX[L/
Y] is important in mediating the interaction of BCL11A
with the COUP-TFII nuclear receptor.
To conﬁrm that RID1 and RID2 are both necessary
and sufﬁcient for the interaction of BCL11A with
COUP-TFII, we introduced substitution mutations
(L319A/Y656A/W659A) in full-length FLAG-BCL11A-
XL that were predicted to prevent COUP-TFII binding
based on the yeast two-hybrid data. We then tested the
effect of these mutations on the interaction of in vitro
translated, isotopically labelled full-length BCL11A-XL
proteins with GST fusion proteins containing the LBDs
of COUP-TFI/NR2F1 and COUP-TFII/NR2F2. We also
included GST-LBD proteins consisting of the LBDs of
TLX/NR2E1 and PNR/NR2E3, which are the close rela-
tives of the NR2F subfamily, and PPARg/NR1C3 whose
sequence is more divergent. As shown in Figure 1D, inter-
actions were detected between wild type BCL11A-XL and
GST-COUP-TFI, GST-COUP-TFII, GST-TLX and
GST-PNR proteins, suggesting BCL11A-XL binds
directly to these LBDs. In contrast, the double mutant
(mRID1/2) failed to bind to NR2E/F LBDs under
similar conditions. No interaction of the wild-type
BCL11A-XL was detected with controls i.e. GST alone,
or GST-PPARg LBD in the presence or absence of the
agonist roziglitazone (Figure 1D). These results suggested
that BCL11A-XL may undergo selective interactions with
different members of the NR family, and that the RID1
and RID2 sequences are required for this function.
To assess the role of RID1 and RID2 sequences in
promoting gene repression by COUP-TFII/BCL11A-XL
complexes, reporter assays were performed using a
RARb2 promoter reporter. The RARb2 gene proximal
promoter contains binding sites for both RARs and
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Figure 1. Novel signature motifs required for interaction of BCL11A-XL with COUP-TFII and related NRs. (A) Yeast two-hybrid interaction
assays mapping the minimal sequences in BCL11A-XL that are required to bind the COUP-TFII LBD. LexA DBD-BCL11A fusion constructs were
expressed in the L40 reporter strain either alone (black bars) or in conjunction with AAD-COUP-TFII LBD (grey bars). Reporter activity in cell-free
extracts is measured as b-galactosidase activities (nmoles/min/mg protein). The data shown represent the mean of triplicate assays, and error bars
represent the standard error of the mean. A schematic representation of BCL11A-XL protein is shown above the chart: black boxes represent
Kruppel-like zinc ﬁngers; white boxes represent the minimal COUP-TFII-interacting regions RID1and RID2. Amino acid numbers for the
boundaries of RID, RID2 and zinc ﬁnger motifs are indicated. (B) Yeast two interactions of AAD-COUP-TFII LBD with RID1, RID2 and
mutants thereof. (C) Alignment of BCL11A RID1 and RID2 sequences conserved in human, mouse, zebraﬁsh, frog (Xenopus laevis), ﬂy
(Drosophila melanogaster) and tick (Ixodes scapularis). (D) GST pulldown experiment showing interaction of in vitro translated 35S-labelled
FLAG-BCL11A-XL wild type or RID1/RID2 double mutant (L319A/Y656A/W659A) with GST or GST-NR LBDs. For GST-PPARg, binding
was assessed in the presence of 1 mM of the agonist roziglitazone (+) or vehicle (). (E–G) Reporter assays in transfected U2OS cells showing effect
of BCL11A proteins on retinoic acid (ATRA)-induced activation of a RARb2-luciferase. Reporter values were obtained after 24 hours exposure of
transfected cells to 106M ATRA (grey bars), or vehicle (black bars). Mean luciferase values from triplicate assays are shown, and error bars
indicate the standard error of the mean.
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COUP-TFs, which have been shown to cooperate to
activate expression of this gene in response to ATRA treat-
ment (34). We conﬁrmed that COUP-TFII can associate
with the RARb2 proximal promoter sequences contain-
ing the COUP-TFII binding site in EMSA assays
(Supplementary Figure S4A). Consistent with this, the
RARb2 reporter was induced by ATRA treatment due to
the action of endogenous RARs, and was further activated
by ectopic expression of COUP-TFII (Figure 1E).
However, co-expression of COUP-TFII with wild-type
BCL11A-XL protein repressed RARb2 reporter activity.
The repressive effect of BCL11A-XL on the RARb2
reporter was inhibited by disruption of both RID1 and
RID2 motifs, whereas only partial rescue was achieved
by disruption of RID1 or RID2 alone (Figure 1F). Thus,
physical interaction of BCL11A-XL with COUP-TFII via
RID1 and RID2 motifs appears to be important for its
corepressor function on the RARb2 promoter. TLX has
also been reported to activate the RARb2 promoter in
response to ATRA (35). Reporter assays conﬁrmed that
TLX-mediated activation of the RARb2 reporter gene in
response to ATRA is repressed by BCL11A-XL to a
similar extent as that observed for COUP-TFII
(Figure 1G). Thus, the ability of by NR2E/Fs to recruit
BCL11A appears to be important for their transcription
regulatory functions.
RID1 and RID2 motifs are required for BCL11A-
mediated repression of human c-globin and Bgl3 genes
To support the above conclusions, we assessed whether
the RID1 and RID2 motifs are important for regulation
of endogenous genes that are reported to be targets of
COUP-TFII and BCL11A. Developmental regulation of
the mammalian b-globin-like locus in erythroid cells is
achieved as a consequence of functional interactions of
BCL11A with transcription factors such as GATA
factors, COUP-TFII, SOX6 and NF-Y (13,14,36,37).
The switch from fetal to adult globin gene expression
requires BCL11A, which acts to repress the fetal-speciﬁc
g-globin genes (Ag and Gg) (13,36,38–40). Similarly,
COUP-TFII has been shown to repress g-globin gene ex-
pression (37,41–43). BCL11A was also reported to repress
the expression of the Bgl3 (AY034471) sequence, a series
of non-coding transcripts located within the globin gd-
intergenic region (Figure 2A), which is co-regulated with
the g-globin genes (38). We therefore set out to ﬁnd
evidence for co-recruitment of COUPTF-II and
BCL11A to regulatory sites in the globin locus, and to
assess whether disruption of BCL11A/COUP-TFII
complexes would impact on transcription of g-globin
and Bgl3.
To select a suitable cell line model, we assessed a
number of leukaemia and lymphoma cell lines for expres-
sion of BCL11A-XL protein. Western blots indicated that
BCL11A-XL is robustly expressed in the B-cell lymphoma
DOHH2 cells and U937 myeloid leukaemia cells, whereas
expression levels are very low in the erythroleukaemia cell
line K562 and the promyelocytic leukaemia HL60 cell line
(Supplementary Figure S5) (13,37,40). Consistent with
current models that BCL11A functions as a repressor of
fetal globin gene expression, very high levels of g-globin
and Bgl3 transcripts were detected in K562 cells using RT
qPCR (Figure 2B). By contrast, g-globin and Bgl3 tran-
scripts were detected at extremely low levels (by several
orders of magnitude) in the DOHH2 cell line (Figure 2B),
which expresses relatively high levels of BCL11A-XL
protein.
We next examined the association of BCL11A and
COUPTFII proteins with key regulatory sites within the
globin locus (depicted schematically in Figure 2A).
Chromatin IP experiments conﬁrmed that BCL11A
protein was detected at DNAse hypersensitive site 3
(HS3) within the locus control region (LCR) in DOHH2
cells, but not in chromatin prepared from K562 cells
(Figure 2C). Moreover, ChIP experiments using
DOHH2-derived chromatin conﬁrmed the presence of
both BCL11A and COUP-TFII at the HS2 and HS3
sites of the LCR, the globin promoter region, the Bgl3
region, but not at the DNAse hypersensitive site 30 to
the locus (HS1-30) (Figure 2D). In contrast, we did not
detect BCL11A-XL at these sites in chromatin prepared
from K562 cells, under similar experimental conditions
(data not shown). These data are consistent with the po-
tential presence of BCL11A/COUP-TFII complexes at
key regulatory sites within the globin locus, and provide
the ﬁrst evidence that COUP-TFII may be involved in
regulating the expression of the putative lncRNA Bgl3.
Analysis of the Bgl3 sequence for potential NR binding
motifs highlighted two distinct regions containing consen-
sus AGGTCA half sites, which were conﬁrmed as COUP-
TFII binding sites in EMSA assays (Figure 2E). Mutation
of these half-sites disrupted the formation of COUP-TFII/
DNA complexes (Figure 2E), while the presence of COUP-
TFII in the complexes was conﬁrmed by antibody
supershifts (Figure 2F). These binding sites in Bgl3
appeared to be speciﬁc for COUP-TFII, as neither TLX/
NR2E1 nor PNR/NR2E3 were capable of strong binding
to these sequences in the EMSA assays (Figure 2G). In
contrast to COUP-TFII, BCL11A did not produce
strong shifts of EMSA probes, although at higher concen-
trations of BCL11A rather diffuse mobility shifts of Bgl3
probes were observed (Supplementary Figure S6A).
Although the mobility of the speciﬁc COUP-TFII/DNA
complexes was altered by BCL11A, suggesting potential
interaction of COUP-TFII and BCL11A in vitro, we did
not observe stable COUP-TFII/BCL11A/DNA complexes
using this assay (Supplementary Figure S6A and B).
Similarly weak binding of BCL11A proteins to the g-
globin promoter sequence in EMSA assays has been
reported (37).Nonetheless, our results are consistent with
reports that BCL11A can be recruited to the Bgl3 locus,
and further suggest a role for COUP-TFII/BCL11A
complexes in regulating Bgl3 transcription.
To assess the effect of RID1/2 mutations on the expres-
sion of Bgl3 and g-globin expression, GFP-tagged
versions of wild type BCL11A-XL or the RID1/2
mutant were ectopically expressed in K562 cells. The
wild type GFP-BCL11A was able to repress expression
of the endogenous Bgl3 and g-globin genes (Figure 2H).
In contrast, expression of the GFP-BCL11A-XL RID1/2
mutant in K562 cells resulted in a signiﬁcantly enhanced
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Figure 2. COUP-TFII binding sites in the Bgl3 locus, and requirement of RID1/RID2 for BCL11A-mediated repression of human g-globin and Bgl3
genes. (A) Schematic representation of the human b-globin locus (not to scale) with boxes indicating the LCR and the embryonic (e), fetal (Gg and
Ag) and adult (d and b) globin genes. The putative lncRNA Bgl3 and the pseudogene HBBP1 are also represented. Approximate regions ampliﬁed by
PCR are indicated by lines over the boxes, including DNAse-I hypersensitive sites in the LCR (HS2 and HS3) and downstream region (HS1-30).
(B) Relative expression of Bgl3 and g-globin transcripts (relative to GAPDH) in DOHH2 and K562 cells. The data are shown on a log scale as
averages of triplicates and the error bars represent the standard deviations. (C) Chromatin IP qPCR revealing detection of BCL11A proteins at the
HS3 site in the globin LCR in DOHH2 cells, but not K562 cells. Control (no antibody) is shown for comparison. The data shown are a
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expression of g-globin over control (Figure 2H), suggest-
ing a dominant negative effect such as sequestration of
other co-repressors. Taken together our results indicate
that repression of endogenous g-globin and Bgl3 genes
by BCL11A is dependent on the functionality of the
RID1 and RID2 motifs, and thus provides strong
evidence for a role for COUP-TFII in regulating expres-
sion of the Bgl3 locus.
BCL11A RID1 and RID2 motifs are highly selective for
the NR2E/F subfamily
To determine whether the RID1 and RID2 sequences
mediate binding to other NRs, we assessed interactions
of LexA-RID1 and LexA-RID2 with a panel of 25 differ-
ent VP16 AAD-NR LBD fusions in Y2H assays. The
nuclear receptor interaction domain (NID) of the human
SRC1 (489–827), containing three LXXLL motifs that
mediate binding to liganded NR LBDs (1), was used for
comparison. Cognate ligands (1 mM) were added to yeast
transformants cultured overnight prior to preparation of
cell-free extracts for reporter assays. As shown in
Figure 3A, the SRC1 NID displayed strong ligand-
stimulated interactions with NR1A2/TRb, NR1B1/
RARa, NR1C3/PPARg, NR1I1/VDR, NR2B1/RXRa,
NR3A1/ERa and NR3C4/AR, as we have previously
reported (29,44). In addition, strong ligand-independent
interactions were observed with the orphan receptors
NR1F1/RORa, NR1F2/RORb, NR2A2/HNF4g,
NR3B1/ERRa, NR5A2/LRH1 and NR6A1/GCNF
(Figure 3A). Similar observations of SRC1 NID binding
to these NR LBDs have been reported in the literature or
protein interaction databases (e.g. BioGRID), with the
exception of GCNF LBD, which, to our knowledge, was
not previously reported to bind SRC1. We did not detect
signiﬁcant interactions of the SRC1 NID with NR0B1/
DAX-1, NR0B2/SHP, NR1D1/Rev-erbb, NR2C1/TR2,
NR2C2/TR4, NR2E1/TLX, NR2E3/PNR, NR2F1/
COUP-TFI, NR2F2/COUP-TFII, NR2F6/EAR2,
NR4A1/Nurr77 or NR4A2/NURR1 under these condi-
tions. In contrast, RID1 and RID2 sequences failed to
bind any of the liganded receptor LBDs tested, or any
orphan receptor LBD that showed an ability to interact
with SRC1 (Figure 3A, middle and right panels).
However, RID1 displayed strong binding to the LBDs
of NR2E1/TLX, NR2E3/PNR, NR2F1/COUP-TFI,
NR2F2/COUP-TFII and NR2F6/EAR2. Similarly,
RID2 showed strong binding to NR2E1/TLX, NR2F1/
COUP-TFI, NR2F2/COUP-TFII and NR2F6/EAR2,
but failed to interact with the photonuclear-speciﬁc
receptor NR2E3/PNR in these experiments. These
results demonstrate a remarkable selectivity of BCL11A
RID1 and RID2 motifs for the NR2E and NR2F subfam-
ily of receptors.
To conﬁrm that the observed interactions of RID1 and
RID2 with NR2E and NR2F proteins in yeast reﬂect
interactions of full-length proteins in mammalian cells,
we performed co-immunoprecipitation experiments.
HEK293 cells were transiently transfected with expression
vectors for FLAG-BCL11A wild-type protein, RID1
mutant (L319A), RID2 mutant (Y656A/W659A) or a
RID1/2 double mutant (L319A/Y656A/W659A) in com-
bination with haemagglutinin (HA)-tagged TLX or PNR,
or untagged COUP-TFII proteins. Co-immunoprecipi-
tation experiments conﬁrmed that wild-type BCL11A-
XL was able to form complexes with COUP-TFII, TLX
and PNR in HEK293 cells (Figure 3B), conﬁrming the
yeast two-hybrid results. Moreover, interactions with all
three NRs were abrogated or reduced by the double
RID1/RID2 mutation (Figure 3B), conﬁrming the contri-
bution of these motifs to establishing the observed inter-
actions. The loss of either RID1 or RID2 reduced the
ability of BCL11A-XL to bind COUP-TFII, suggesting
both motifs may be required to form bivalent contacts
with homodimer or heterodimer complexes of COUP-
TFII. TLX on the other hand was more sensitive to mu-
tations in RID2, as RID1 mutation (L319A) alone had
little effect on its ability to form a complex with
BCL11A-XL under these conditions. In contrast,
mutation of RID2 had no deleterious effect on PNR
binding, suggesting that only RID1 is required for inter-
action with this nuclear receptor, consistent with the yeast
two-hybrid data (Figure 3A). Thus, these data conﬁrm
that NR2E/F subfamily members make selective
contacts with BCL11A proteins through RID1/RID2
motifs, albeit with differing sensitivities to the ablation
of either motif.
TLX is an important regulator of stem cell fate in fore-
brain and retina (45), and defects in its expression are
associated with behavioural abnormalities, blindness and
glioblastoma as reviewed in (46). In addition to its role in
development, TLX expression has been detected in neural
stem cells in adult brain within cells lining the
subventricular zone, and the subgranular layer of the
dentate gyrus, as well as in striatum and cortex (47).
PNR expression in the adult is restricted to the
Figure 2. Continued
representative experiment showing the average of triplicates, with error bars indicating standard deviations. (D) ChIP qPCR detection of BCL11A or
COUP-TFII proteins at the LCR HS2 and HS3 sites, the g-globin promoter, the Bgl3 sequence, and the HS1-3’ site. (E) EMSA indicating the
presence of COUP-TFII binding sites within the human Bgl3 sequence. Double-stranded DNA probes (end labelled with g32P) were incubated with
cell-free extracts of HEK293 cells expressing recombinant Nuclear Receptor or BCL11A-XL proteins, or mock transfected as indicated (as described
in Materials and Methods). The Bgl3 transcribed region is represented schematically, and the relative positions of the probes used in the EMSA
experiments are indicated. Free probes and speciﬁc COUP-TFII/DNA complexes are indicated on the image. The sequences of the probes which
showed speciﬁc complex formation with COUP-TFII are represented below the gel image. Putative HRE half sites are overlined and sequence
changes made to disrupt these half sites in ‘mutated’ probes are indicated. (F) EMSA supershift experiment to validate of the identity of COUP-TFII
containing complexes using a COUP-TFII speciﬁc antibody as described in Materials and Methods. (G) Comparison of the abilities of COUP-TFII,
TLX or PNR proteins to bind the indicated Bgl3 probes. (H) RT-qPCR experiments indicating the effects of GFP, GFP-BCL11A and GFP-
BCL11A(RID1/2)mut on endogenous g-globin and Bgl3 expression (relative to GAPDH) in transfected K562 cells. The experiment was performed in
triplicate with error bars indicating standard deviations, and P values indicated (*P< 0.05) (**P< 0.005).
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photoreceptor cell layer of the retina (48). Previous studies
have reported the detection of the BCL11A transcripts in
both developing and adult murine brain (24). To examine
BCL11A protein expression in brain, we performed
immunohistochemical staining on mouse brain tissue
sections using an antibody that detects both the L and
XL isoforms. Strong expression of BCL11A was
detected in cortical regions and also in pyramidal cell
layers in the CA1 and CA3 regions of the hippocampus.
BCL11A protein is localized to the nucleus in these cells,
e.g. as shown for the pyramidal layer of the hippocampus
(Figure 3C). Western blots on tissue homogenates con-
ﬁrmed the expression of BCL11A in mouse hippocampus
and cortex, with lower levels detected in the striatum and
very low levels in the cerebellum (Figure 3D). In contrast,
TLX protein was detected in all four of these regions
(Figure 3D). Importantly, immunoprecipitation of
BCL11A proteins from cortex revealed co-precipitation
of TLX but not the b-actin control (Figure 3E), conﬁrm-
ing the existence of endogenous complexes of TLX and
BCL11A in vivo. We also attempted to detect PNR/
BCL11A complexes in whole eye homogenates from
adult mice. However, although PNR was readily
immunoprecipitated from these extracts, we were unable
to detect expression of BCL11A in the eye (data not
shown), suggesting that PNR/BCL11A interactions may
occur only during embryo development.
RID interaction requires the F221 residue in Helix 3 of
the COUP-TFII LBD
We noted from the structure of the COUP-TFII LBD
(PDB:3CJW) that residues in Helix 3 (F221, V224,
R228) and Helix 5 (I238, V242, R246) are likely to be
positioned to come in contact with a-helices in docking
cofactors (Figure 4A). We therefore generated AAD-
COUP-TFII LBD substitution mutants for Y2H assays.
As shown in Figure 4B, substitution of F221 with alanine
completely abrogated the binding of both RID1 and
RID2, indicating that this residue is essential for binding
Figure 3. Selective nuclear receptor binding by BCL11A RID1 and RID2 motifs. (A) Yeast two-hybrid interactions of VP16 AAD-fused NR-LBDs
with LexA DBD-fused SRC1 NID 489-827 (containing LXXLL motifs), or BCL11A RID1 and RID2 sequences as indicated. The results shown
represent the mean reporter (b-galactosidase) activity± standard error of triplicate experiments. Cognate ligands if known were added (grey
columns), whereas vehicle only or no ligand is represented by black columns. (B) Co-immunoprecipitation of recombinant NR/BCL11A complexes.
HEK293 cells co-transfected with COUP-TFII, HA-TLX or HA-PNR expression vectors in combination with FLAG-BCL11A-XL (WT), or the
mutants mRID1/2 (L319A/Y656A/W659A), mRID1 (L319A) or mRID2 (Y656A/W659A). FLAG-tagged proteins were immunoprecipitated with
anti-FLAG beads and associated proteins detected using the indicated antibodies. (C) Immunohistochemical staining of BCL11A proteins showing
strong staining in the pyramidal cell layer (Py) extending from CA1 to the dentate gyrus (DG). Right panel shows magniﬁcation of the boxed region
showing nuclear staining of BCL11A. (D) Immunodetection of TLX and BCL11A proteins in mouse brain tissue homogenates as indicated.
(E) Co-immunoprecipitation of endogenous TLX and BCL11A proteins from adult mouse cerebral cortex tissue extract.
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Figure 4. Probing the binding interface between NR2E/Fs and BCL11A. COUP-TFII LBD Helix 3 residues facilitate docking of RID1 and RID2:
(A) Cartoon representation (left panel) of the COUP-TFII LBD (PDB: 3CJW) (49) generated using PyMol open source molecular visualization tool.
The AF2 helix is shown in yellow. Key residues in Helix 3 (magenta) and Helix 5 (orange) are indicated. Right panel shows a surface representation
of the COUP-TFII LBD complex highlighting the exposed phenylalanine F221 (red) and R228 (blue) which hydrogen bonds to the AF2 helix. In this
view, V224 is buried beneath the AF2 helix. (B) Yeast two-hybrid interactions of LexA-BCL11A RID1 and LexA-BCL11A RID2 with AAD-COUP-
TFII LBD wild type or mutant proteins as indicated. The right panel shows the effect of these mutations on heterodimer formation with LexA
COUP-TFII LBD. The results shown represent the mean reporter (b-galactosidase) activity± standard error of triplicates. Differential sequence
requirements for binding of RID1 and RID2 to NR2Es and NR2Fs: Yeast two-hybrid interactions of (C) LexA-BCL11A RID1 and (D) LexA-
BCL11A RID2 alanine scan mutant series in combination with AAD-NR LBD constructs as indicated. The results shown represent the mean
reporter (b-galactosidase) activity± standard error of triplicates. The sequence motif required for the binding of each NR LBD is indicated below
the graph.
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to the F/YSXXLXXL/Y helices. The ability of the F221A
mutant to form homodimers with wild-type COUP-TFII
LBD was not affected, showing that this mutation is
unlikely to perturb the overall structure of the domain
(Figure 4B). While the V224A mutant appeared unable
to bind RID2, RID1 binding appeared unaffected
(Figure 4B). However, western blots indicated that this
mutant was expressed at a 2-fold lower level than other
constructs in this series (Supplementary Figure S2C).
Consistent with this, the V224A also showed reduced
reporter activation due to homodimer formation (by
about 2.5-fold), which we attribute to its slightly reduced
expression level. Mutated LBDs with replacements of
I238, V242 or R246 in Helix 5 (or K362 in Helix 10,
data not shown) retained substantial ability to bind
RID1 or RID2, albeit that binding of RID1 by the
R246A mutant was reduced. This suggests that these
residues are not essential for binding of COUP-TFII
LBD to BCL11A. Substitution of R228, which is the
equivalent of the conserved lysine in the charge clamp
contacting LXXLL motifs in liganded NRs, did not
disrupt the interaction of the COUP-TFII LBD with
RID1 or RID2. Indeed, reporter activation due to inter-
action of the R228A mutant with RID1 was enhanced in
comparison with the wild-type LBD (Figure 4B). As R228
is predicted to stabilize the orientation of H12 within the
cofactor docking site (49), it is possible that disruption of
this salt bridge might facilitate H12 displacement by co-
factors. We conclude from these experiments that Helix 3
is likely to form part of the RID1 and RID2 docking site
on the COUP-TFII LBD surface. While F221 appears
critical for binding RID1 and RID2, V224 may be essen-
tial for RID2 binding only. This is suggestive of subtle
differences in how the two motifs contact COUP-TFII.
In the ‘auto-inhibited’ structure of the COUP-TFII
LBD, the activation function-2 (AF2) helix occupies the
cofactor binding groove on the LBD surface (Figure 4A).
It has been postulated that binding of COUP-TFII to
retinoic acid (ATRA) ligand would alter the LBD struc-
ture (49) thus facilitating its interaction with cofactors. We
did not observe any effect of ATRA on the binding of
coactivator or corepressor peptides in two-hybrid assays,
or on interactions of full-length proteins in vitro (data not
shown), although we cannot rule out the presence of low
levels of endogenous ATRA in these assays. However,
deletion of the COUP-TFII AF2 helix (393–414)
resulted in a complete loss of interaction with RID1 and
RID2, and a failure to form heterodimers with full-length
LBD (Supplementary Figure S2D), suggesting that the
AF2 helix is required to stabilize the COUP-TFII LBD
structure.
Differential requirements of COUP-TFs, TLX and PNR
for RID1 and RID2 sequences
To determine whether members of the NR2E/F subfamily
make similar contacts with the RID1 and RID2 motifs,
yeast two-hybrid assays were performed to assess the
interactions of NR2E/F receptors with the mutant RID1
and RID2 constructs described in Figure 1B. As shown in
Figure 4C and D, COUP-TFI showed a similar pattern of
interactions with RID1 and RID2 mutants as found for
COUP-TFII (Figure 1B), showing a requirement for
FSXXLXXL in RID1 (Figure 4C), and VYSXWLXXY
in RID2 (Figure 4D). The EAR2/NR2F6 LBD showed
only 2-fold lower reporter activation due to interactions
with F315A, suggesting this residue is less critical for its
recruitment of RID1 (Figure 4C). Similarly, EAR2
engagement of RID2 was somewhat different to COUP-
TFI/II, as alanine substitution of Y656 or S657 had only a
minor effect on reporter activation. This suggests a re-
quirement for VXXXWLXXY in RID2 to bind EAR2.
TLX binding to RID1 did not require S316A
(Figure 4C) and similarly S657 in RID2 was dispensible
for TLX recruitment (Figure 4D). Combined with other
interaction data, this suggests that TLX requires
FXXXLXXL and YXXXLXXY in RID1 and RID2,
respectively. Interestingly, the SANT domain repressor
proteins Atrophin-1 (ATN1) and RERE/ATN2, which
can bind TLX (50) and PNR (51), contain a motif
termed the ATRO box motif that is required for inter-
action with TLX (50), This sequence (LXXL) shows
partial overlap with the C-terminal portions of RID1
and RID2 (Figure 5A).
The interaction of PNR with BCL11A was somewhat
distinct from other members of the NR2E/F subfamily, in
that it was found to be dependent on RID1, but much less
so on the integrity of RID2. Similar to COUP-TFI/II and
TLX, binding of PNR to RID1 required F315, L319 and
L322. However, unlike other NRs, PNR was also sensitive
to mutation of R317 and R320 (Figure 4C). This result
indicates a requirement for the sequence FXRXLRXL to
promote stable interaction of BCL11A with PNR. As the
RID2 motif lacks equivalent arginine residues at these
positions, this might account for the apparent preference
of PNR for RID1.
Conservation of F/YSXXLXXL/Y motifs in NSD1 and
other proteins
We have shown here that BCL11A RID1 and RID2 se-
quences mediate selective interactions with the NR2E/F
subfamily, and that F/YSXXLXXL/Y motifs are
conserved in vertebrate, insect and arthropod orthologs
of BCL11A/B proteins (Figure 1C). Sequence similarity
searches revealed the existence of similar motifs in other
transcriptional regulators including the NR cofactor
SOTOS overgrowth syndrome gene product NSD1
(Figure 5A). NSD1 is a SET domain lysine methyltrans-
ferase protein containing two regions that exhibit differ-
ential interactions with NRs (52). The sequence 738–788
was reported to bind to the LBD of RARa in the absence
of ligand, whereas addition of ATRA disrupted this inter-
action (52), similar to the binding behaviour of
corepressors such as NCOR and SMRT with RARs and
other liganded NRs (3–5). In contrast, an adjacent
region of the NSD1 sequence (termed NID+L) displayed
binding properties typical of a coactivator in that it bound
to the LBDs of RARa, RXRa, ERa and TRa, in a ligand-
dependent manner. This function was mapped to a
LXXLL-type sequence deﬁned as the sequence NSD1
803-FXXLL-807 (52), which is coincident with the
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RID1-like sequence 803-FSXXLXXL-810 (Figure 5A).
To test whether this sequence would facilitate interactions
with NR2E/F proteins, as predicted by our ﬁndings, we
performed two-hybrid assays. As shown in Figure 5B, the
construct LexA-NSD1 790-818, which contains an RID1-
like motif, showed strong ligand-dependent interactions
with NR1B1/RARa, NR2B1/RXRa and NR3A1/ERa
as reported previously, but also with NR1C3/PPARg,
NR1I1/VDR, NR1A2/TRb and NR3C4/AR. Substantial
constitutive interaction with RXRa and PPARg occurred
in the absence of exogenous ligand for the reasons previ-
ously outlined, consistent with similar results for SRC1
and MED1 NIDs (1,29,44). In addition, as observed for
SRC1 NID, strong constitutive interactions were observed
with the orphan receptors NR1F1/RORa, NR1F2/
RORb, NR2A2/HNF4g, NR3B1/ERRa, NR5A2/LRH1
and NR6A1/GCNF, but not with NR0B1/Dax-1,
NR0B2/SHP, NR1D2/Reverbb, NR2C1/TR2, NR2C2/
TR4, NR4A1/Nurr77, NR4A2/NURR1 or NR2E3/PNR
(Figure 5B). However, unlike the SRC1 NID (Figure 3A),
the NSD1 NID+L containing construct also showed
strong interactions with NR2F1/COUP-TFI, NR2F2/
COUP-TFII, NR2F6/EAR2 and NR2E1/TLX
(Figure 5B). This result is consistent with the hypothesis
that a FSXXLXXL sequence within NSD1 can mediate
interactions with the NR2E/F subfamily. The failure of
the NSD1 motif to interact with PNR LBD in these
assays is also consistent with the observed differential
sequence requirement of PNR e.g. for a FXRXLRXL
sequence, as present in BCL11A proteins.
Our data indicate that short alpha helical motifs present
in cofactors determine differential NR-binding selectivity.
Although BCL11A and NSD1 both have FSXXLXXL
sequences, BCL11A is highly selective for NR2E/F sub-
family, whereas NSD1 shows a much broader range of
interactions. We hypothesized that this differential select-
ivity may be due to the sequence context, which we have
previously shown to be important in determination of NR
selectivity (1,29,44). In contrast to the BCL11A RID1, the
NSD1 NR-binding sequence is coincident with FXXLL
and LXXML motifs, both of which are LXXLL
variants that can potentially dock with ligand-dependent
NRs. Thus, we reasoned that the NSD1 motif may
contain structural features that are recognized by different
NR subgroups. To test this, we undertook substitution
mutagenesis of the NSD1 motifs to determine the effects
on binding of NRs from different binding classes. As
shown in Figure 5C, interaction of the NSD1 motif with
the LBD of TLX binding required a FSXLLXML
sequence, whereas binding to ERa or LRH1 LBDs
required the sequence SXLXXML, which more resembles
the LXXLL signature motif. These differential
A
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BCL11B 358 SPAMD FSRRLREL AGNSSTPP  378  NR2E/F
BCL11B 703 PSENV YSQWLVGY AASRHFMK  723  NR2F;NR2E1
NSD1  798 EPDYK FSTLLMML KDMHDSKT  818  NR1ABC;2B;3C
FOG2  927 PNGNL FSSHLATL QGLKVFSE  947  NR2F2 
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Figure 5. A functional FSXXLXXL motif in NSD1. (A) Sequence alignment showing the presence RID1/RID2 and ATRO box sequences in NR2-
binding cofactors. The sequences are based on human Refseq entries in NCBI Protein or Gene databases. Conserved FS and L residues are shaded.
Predicted alpha-helicity of the BCL11A RID1 sequence is shown above the alignment. (B) Yeast two-hybrid interactions of LexA DBD-fused NSD1
790–818 with AAD-NR-LBD constructs as indicated. Cognate ligands if known were added (grey columns), whereas vehicle only or no ligand is
represented by black columns. The results shown represent the mean reporter (b-galactosidase) activity± standard error of triplicate experiments.
(C) Binding of LexA NSD1 790–818 wild type or mutants to AAD-TLX, AAD-ERa, AAD-LRH1 LBDs. The sequence of the NSD1 NID+L region
(790–818) is indicated, and the sequence motif required for binding to different NR LBDs is indicated above the bar charts.
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requirements for docking with different NR LBDs suggest
that cofactor motifs have co-evolved with NR LBD se-
quences to achieve selective interactions. Thus, conserved
alpha helical motifs present in NR cofactors have evolved
features that accommodate their selective binding to
different subsets of NRs within the superfamily.
DISCUSSION
We have identiﬁed novel sequence motifs in the develop-
mental co-repressor BCL11A that facilitate its selective
interactions with members of the NR2E/F subfamily.
These motifs, RID1 and RID2, bear resemblance to the
LXXLL and LXXXLXXXI/L canonical motifs found in
NR coactivators and corepressors, respectively. The
BCL11A motifs are highly selective for the NR2E/F sub-
family, in contrast with LXXLL motifs found in
coactivators such as SRC1 (Figure 3A) and MED1 (data
not shown), which do not show strong binding to these
NRs. Our study also reports the interaction of TLX/
NR2E1 and PNR/NR2E3 with the developmental co-
repressor BCL11A.
Interactions of BCL11A with COUP-TFII were known
from previous studies, and there is evidence that these
proteins cooperate to regulate expression of genes in the
globin locus and are thus important in fetal to adult
haemoglobin switching. Early studies described mutations
within the human g-globin promoter that are associated
with the persistent expression of the g-globin genes in
adults, which were later shown to function as composite
COUP-TFII/GATA binding sites (53). More recently, it
has been reported that a non-coding sequence in the
globin locus termed Bgl3 shows co-expression with
g-globins (40). Moreover, both of these transcripts have
been shown to be regulated by BCL11A (13,40), although
the function of the Bgl3 lncRNA remains to be
determined. We have shown here that similar to COUP-
TFII-dependent regulation of the g-globin genes (37,42),
the Bgl3 locus contains binding sites for COUP-TFII, con-
ﬁrmed in EMSA and ChIP qPCR assays, suggesting Bgl3
transcription is regulated by this factor. Indeed, using the
K562 erythroleukemia cell line which contains only very
low levels of BCL11A (Supplementary Figure S5), we
showed that exogenous BCL11A-XL can repress expres-
sion of the Bgl3 and g-globin genes, and that this is
dependent on the functionality of the RID1 and RID2
motifs. These results indicate that interaction of
BCL11A and COUP-TFII proteins is important for regu-
lation of transcription within the globin locus. However,
understanding the precise nature of these functional inter-
actions is challenging, given that both factors may bind
DNA/chromatin independently, co-dependently or via
associations with a complex network of other transcrip-
tion factors (GATA1/2, SOX6, NF-Y) and co-repressors
(NuRD, HDACs, SIRT1, BCL6, Co-REST, NCoR) at
globin gene regulatory sites, as shown schematically in
Figure 6. Further studies will be required to determine
the precise mechanisms involved.
TLX is a key stem cell fate regulator in the developing
forebrain and eye (45,54). In adult mice, TLX is expressed
in the subventricular zone of the lateral ventricle and
subgranular layer of the dentate gyrus, both of which
are regions associated with neurogenesis (45,55).
Consistent with in situ hybridization studies on BCL11A
transcripts (24), we detected substantial expression of
BCL11A-XL and L isoforms in the hippocampus and
cortex, and to a lesser extent in striatum (Figure 3C and
D). Moreover, we were able to demonstrate that TLX and
BCL11A proteins can be co-immunoprecipitated from
extracts of adult mouse cerebral cortex (Figure 3E). This
suggests that BCL11A may function as a corepressor in
TLX-mediated gene regulation in adult neuronal tissues.
While genes that are regulated by TLX/BCL11A remain
to be identiﬁed, a previous study has shown that TLX can
activate the RARb2 promoter in response to ATRA (35).
Reporter assays conﬁrmed that TLX-mediated activation
of the RARb2 reporter gene in response to ATRA is
repressed by BCL11A to a similar extent as observed for
COUP-TFII (Figure 1F and G).
PNR expression in adult mammalian tissues is conﬁned
to photoreceptors in the retinal epithelial layer. Knockout
studies have shown that PNR suppresses cone gene ex-
pression in photoreceptors, thus committing precursor
cells to the rod lineage. PNR acts in conjunction with
cone rod homeobox (CRX) and neural retina leucine
zipper (NRL) to regulate rod and cone gene expression
in a cell-speciﬁc manner, and appears to direct both
positive and negative regulation (56). The mechanism by
which this is achieved, and the cofactors that are involved
remain unclear, although it has been reported that PNR
can recruit Atrophins (51) and the Ret-CoR corepressor
complex (57). Our ﬁndings indicate that PNR can also
interact directly with BCL11A-XL, as demonstrated by
yeast two-hybrid, in vitro studies and in transfected cells
SOX6
GATA1/2
Mulvalent Interacons Long distance interacons
LCR looping
BCL11A
COUP-TFII
COUP-TFII
NFY
GATA1/2
SOX6
NURD; Co-REST;NCOR
BCL11A
COUP-TFII BCL11A
DNA/chroman
A B
C D
–dependent
BCL11A
Chroman and TF-dependent
COUP-TFII
BCL11A
BCL11A
SOX6
Figure 6. Schematic model showing possible modes of recruitment of
BCL11A to regulatory sites in the globin locus, and the formation of
functional complexes with COUP-TFII; (A) Direct, independent
recruitment of both factors to DNA sequences or chromatin; (B) co-
dependent recruitment through protein–protein interactions mediated
by F/VSXXLXXL/Y motifs; (C) Multivalent interactions between dif-
ferent factors assembled in situ; (D) Long distance interactions
involving transcription factors and chromatin regulator complexes e.g
due to chromatin looping.
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(Figures 1 and 3). However, as we did not detect expres-
sion of BCL11A -L or XL isoforms in the eye (data not
shown), it remains to be established whether coexpression
of BCL11A and PNR occurs in other tissues, such as in
the developing embryo. Alternatively, it is possible that
PNR interacts with BCL11B or other proteins containing
RID1-related motifs.
Both TLX and PNR have been reported to bind the
Atrophin/RERE proteins that function as transcription
corepressors (50,51). Sequence alignments revealed that
the F/YSXXLXXL/Y motifs identiﬁed in BCL11A show
partial similarity to a motif deﬁned in Atrophin/RERE
proteins that mediates binding to TLX (Figure 5A),
termed the ATRO box (50). Although saturation muta-
genesis to deﬁne the ATRO box remains to be determined,
it has been shown that the sequence LXXL is required for
association of atrophins with TLX (50). It remains to be
established whether atrophins are selective for PNR and
TLX, or whether atrophins can form complexes with
COUP-TFs or other NRs. The RNA helicase Ret-CoR/
DHX30 was isolated in a yeast two-hybrid screen of
human brain cDNAs for PNR-binding proteins (57).
Like atrophins, Ret-CoR is a component of a HDAC
complex, which was shown to act as a corepressor for
GAL4-PNR-mediated transcription. The interaction of
Ret-CoR with PNR was reported to be dependent on
two copies of the sequence (LXXVI) (57), which has simi-
larity to CoRNR box and ATRO box motifs. However, it
is not been established if this protein can bind other NRs.
Interestingly, while Ret-CoR/PNR complexes were shown
to occur in the developing retina, expression of Ret-CoR
in adult retinal tissues was very low (57). Thus interactions
of RetCoR and BCL11A/B with PNR may be restricted to
embryonic development.
Biochemical and structural studies have revealed that
NR LBDs undergo conformational changes in response
to agonist/antagonist binding, and that these changes
regulate interactions with coactivators and corepressors.
Crystal structures of apo- and holo-receptor LBDs have
demonstrated the conformational ﬂexibility of the AF2
helix in ‘activating’ or ‘repressive’ conformations of the
LBD, and this positioning is thought to facilitate the
docking of coactivators and corepressors [reviewed in
(53,58)]. Both coactivator (LXXLL) peptides and repres-
sor peptides occupy the same docking site, suggesting a
mutually exclusive mechanism of interaction. Among the
NR2E/F subfamily, only the crystal structure of the
unliganded COUP-TFII monomer has been determined,
and this shows the AF2 helix occupying the cofactor
binding pocket on the LBD surface (49). Based on other
LBD structures, this autoinhibitory conformation is likely
to be refractory to cofactor binding. Thus, the question
remains as to how corepressors and coactivators dock
with COUP-TFII LBD. Our mutagenesis assays indicate
that residues in Helix 3 that help to accommodate the AF2
helix in the ‘auto-inhibited’ LBD are involved in the
binding of BCL11A while F221 is required to facilitate
both RID1 and RID2, V224 appears to be essential for
RID2 only. These results are suggestive of subtle differ-
ences in how RID1 and RID2 motifs dock with the
COUP-TFII LBD, possibly involving different contacts
with cofactor binding groove to displace the AF2 helix.
This is reminiscent of the different binding mechanisms
observed for the interaction of the ID1/CoRNR1and
ID2/CoRNR2 motifs with the RAR LBD (59).
Structural studies will be required to reveal how RID1
and RID2 sequences dock with NR2E/F LBDs.
Although COUP-TFs can synergize with coactivators to
activate transcription in reporter assays (49) evidence for
direct interactions of the COUP-TFs with the coactivators
is lacking. In our hands, COUP-TFII LBD binding to full
length proteins or LXXLL peptides derived from SRC1 or
MED1/TRAP220 is not robust enough to be detected in
Y2H or GST pulldown assays (Figure 3A and data not
shown). Thus, the mechanism by which COUP-TFII acti-
vates transcription remains to be determined. It is possible
that COUP-TFs may recruit coactivators indirectly via
heterodimer partners, or that the observed positive
effects of COUP-TFII on transcription are due to dere-
pression mechanisms, such as sequestering corepressors
away from target genes. Although the NR-binding
LXXLL motifs in SRC1 (Figure 3) and MED1/
TRAP220 (data not shown) appear to interact exclusively
with ‘activating’ NRs, we have shown here that the NR
binding motif of NSD1 has features that can promote its
binding to both ‘activating’ and ‘repressive’ NRs.
Interestingly, the failure of PNR to bind NSD1
FSXXLXXL motif indicates a more speciﬁc sequence
requirement consistent with the mutagenesis data in
Figure 4C. It remains to be investigated whether NSD1
forms complexes with NR2E/Fs in vivo, in particular in
brain where both proteins are highly expressed.
In addition to BCL11A/B and NSD1, F/YSXXLXXL/Y
motifs are found in other proteins including NRs,
NR cofactors and other gene regulatory proteins (see
Supplementary Figure S7). It remains to be established
whether these motifs can promote direct interactions
with NR2E/F subfamily members, although for some
there is previous evidence that such complexes exist. For
example, the zinc ﬁnger repressor Friend of GATA
(FOG2) is known to interact with both GATA and
COUP-TFII proteins to regulate globin gene expres-
sion in haematopoietic tissues (60,61). Intriguingly, the
C-terminal sequence 848–1152, which mediates interaction
with COUP-TFII, comprises a FSXXLXXL motif
(Figure 5A). Further studies will be required to determine
whether RID1/RID2 motifs are unique to the BCL11A/B
and NSD1 proteins or are more widespread amongst
cofactors for COUP-TFs, TLX and PNR.
In summary, we have deﬁned a new signature motif
selective for the NR2E/F subfamily and highlighted pre-
viously unknown roles for BCL11A/B and NSD1 proteins
in the gene regulation by COUP-TFs, TLX and PNR.
Moreover, our study provides new insights into how
subtle variations in short sequences at the interface of
NR/cofactor complexes determine selectivity.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online,
including [62–67].
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